Aktuellt
SENASTE
Redeye maintains the valuation of BioArctic at SEK 265 per share after today's Q4 report. Based on consistent and solid clinical data, we calculate with a reasonably high likelihood of conditional approval in the US already this year. The endpoint readout in September would serve as a basis for a full approval and for an application in Europe and Japan in 2023.
LÄS MER
